kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Biotinylated Human VEGF165 Protein, His,Avitag™, 25µg  

Biotinylated Human VEGF165 Protein, His,Avitag™, 25µg

Recombinant Biotinylated Human VEGF165 Protein, AA vAla 27 - Arg 191, expressed from human HEK293 cells, His, Avitag™

Synonym: recombinant, human, biotinylated protein, RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF, VEGF165, biotin-VEGF, btn-VEGF

More details


325,00 €

is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

Recombinant Biotinylated Human VEGF165, His,Avitag (VE5-H82Q0) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4). Predicted N-terminus: His 

Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 22.4 kDa (monomer). As a result of glycosylation, the protein migrates as 25-33 kDa (monomer) under reducing (R) condition, and 42-55 kDa (homodimer) under non-reducing (NR) condition (SDS-PAGE).

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE. 

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "VEGF-A promotes the motility of human melanoma cells through the VEGFR1-PI3K/Akt signaling pathway"
Koizumi, Shintani, Hayashido et al
In Vitro Cell Dev Biol Anim (2022)
(2) "Effect of bone-shaped nanotube-hydrogel drug delivery system for enhanced osseointegration"
Yuan, Xu, Song et al
Biomater Adv (2022) 137, 212853
(3) "A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment"
Kuo, Chou, Lien et al
Cancer Immunol Immunother (2022)
Showing 1-3 of 1230 papers.

The following products could also be interesting for you: